Whole revenue rose to Rs 1,037 crore for the fourth quarter as in opposition to Rs 933 crore within the year-ago interval, Syngene Worldwide stated in a regulatory submitting.
For the yr ended March 31, 2025, Syngene reported a web revenue of Rs 496 crore as in opposition to Rs 510 crore in FY24.
Whole revenue rose to Rs 3,714 crore for the fourth quarter as in opposition to Rs 3,579 crore within the 2023-24 fiscal yr.
The corporate stated its board, which met on Wednesday, really helpful a closing dividend of Re 1.25 per share of Rs 10 every for the 2024-25 monetary yr.
“The total yr outcomes, led by reported income development of 4 per cent, are in keeping with our January steerage, reflecting a resilient efficiency in a difficult yr. After a muted first half, pushed by a sectoral downturn in US biotech funding, we’re inspired to see a return to development within the second half of the yr,” Syngene Worldwide MD and CEO Peter Bains said. Wanting on the yr forward, whereas the broader international market dynamics stay unsure, the corporate expects the enterprise momentum to proceed with pipeline construct in each small and huge molecules, supported by new pilot packages and conversion of current pilots in discovery providers. “On an underlying foundation for FY26, we anticipate income development within the early teenagers reflecting a broad-based development throughout analysis, growth and manufacturing providers,” Bains stated.
Adjusted for stock balancing in giant molecule business manufacturing at shopper degree, the reported income development is prone to be at mid-single digit, he added.
Shares of the corporate on Wednesday ended 1.99 per cent up at Rs 750.05 apiece on the BSE.
